Journal of Shanghai Jiao Tong University (Medical Science) ›› 2023, Vol. 43 ›› Issue (8): 1056-1063.doi: 10.3969/j.issn.1674-8115.2023.08.015
• Review • Previous Articles
ZHOU Wanzhen(), TENG Yincheng()
Received:
2023-04-23
Accepted:
2023-06-19
Online:
2023-08-28
Published:
2023-08-28
Contact:
TENG Yincheng
E-mail:Apccy7@163.com;teng_yc@126.com
Supported by:
CLC Number:
ZHOU Wanzhen, TENG Yincheng. Research progress of the role of non-canonical Wnt signaling pathway in ovarian cancer and its potential therapeutic implications[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(8): 1056-1063.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2023.08.015
1 | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. |
2 | ZHANG Y, WANG X. Targeting the Wnt/β-catenin signaling pathway in cancer[J]. J Hematol Oncol, 2020, 13(1): 165. |
3 | NGUYEN V H L, HOUGH R, BERNAUDO S, et al. Wnt/β-catenin signalling in ovarian cancer: insights into its hyperactivation and function in tumorigenesis[J]. J Ovarian Res, 2019, 12(1): 122. |
4 | KONI M, PINNARÒ V, BRIZZI M F. The Wnt signalling pathway: a tailored target in cancer[J]. Int J Mol Sci, 2020, 21(20): 7697. |
5 | ASEM M S, BUECHLER S, WATES R B, et al. Wnt5a signaling in cancer[J]. Cancers (Basel), 2016, 8(9): 79. |
6 | VANDERVORST K, HATAKEYAMA J, BERG A, et al. Cellular and molecular mechanisms underlying planar cell polarity pathway contributions to cancer malignancy[J]. Semin Cell Dev Biol, 2018, 81: 78-87. |
7 | BUENO M L P, SAAD S T O, ROVERSI F M. Wnt5a in tumor development and progression: a comprehensive review[J]. Biomed Pharmacother, 2022, 155: 113599. |
8 | LOJK J, MARC J. Roles of non-canonical Wnt signalling pathways in bone biology[J]. Int J Mol Sci, 2021, 22(19): 10840. |
9 | FORD C E, PUNNIA-MOORTHY G, HENRY C E, et al. The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer[J]. Gynecol Oncol, 2014, 134(2): 338-345. |
10 | PENG C J, ZHANG X L, YU H L, et al. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer[J]. Int J Gynecol Cancer, 2011, 21(2): 280-288. |
11 | JIN P, SONG Y, YU G Y. The role of abnormal methylation of Wnt5a gene promoter regions in human epithelial ovarian cancer: a clinical and experimental study[J]. Anal Cell Pathol (Amst), 2018, 2018: 6567081. |
12 | HENRY C E, LLAMOSAS E, DJORDJEVIC A, et al. Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer[J]. Oncogenesis, 2016, 5(5): e226. |
13 | ZHANG H L, QIU J R, YE C P, et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer[J]. Sci Rep, 2014, 4: 5811. |
14 | KARIN-KUJUNDZIC V, KARDUM V, SOLA I M, et al. Dishevelled family proteins in serous ovarian carcinomas: a clinicopathologic and molecular study[J]. APMIS, 2020, 128(3): 201-210. |
15 | LIU R, CHENG J L, CHEN Y N, et al. Potential role and prognostic importance of dishevelled-2 in epithelial ovarian cancer[J]. Int J Gynaecol Obstet, 2017, 138(3): 304-310. |
16 | XU W W, GU J J, REN Q L, et al. NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway[J]. Tumor Biol, 2016, 37(4): 4493-4500. |
17 | XIN B, JI K Q, LIU Y S, et al. NFAT overexpression correlates with CA72-4 and poor prognosis of ovarian clear-cell carcinoma subtype[J]. Reprod Sci, 2021, 28(3): 745-756. |
18 | CHEN S, WANG J, GOU W F, et al. The involvement of RhoA and Wnt5a in the tumorigenesis and progression of ovarian epithelial carcinoma[J]. Int J Mol Sci, 2013, 14(12): 24187-24199. |
19 | CHEHOVER M, REICH R, DAVIDSON B. Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma[J]. Virchows Arch, 2020, 477(2): 249-258. |
20 | KOTRBOVÁ A, OVESNÁ P, GYBEL' T, et al. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer[J]. Theranostics, 2020, 10(2): 537-552. |
21 | AZIMIAN-ZAVAREH V, DEHGHANI-GHOBADI Z, EBRAHIMI M, et al. Wnt5a modulates integrin expression in a receptor-dependent manner in ovarian cancer cells[J]. Sci Rep, 2021, 11(1): 5885. |
22 | MENCK K, HEINRICHS S, BADEN C, et al. The WNT/ROR pathway in cancer: from signaling to therapeutic intervention[J]. Cells, 2021, 10(1): 142. |
23 | HENRY C E, EMMANUEL C, LAMBIE N, et al. Distinct patterns of stromal and tumor expression of ROR1 and ROR2 in histological subtypes of epithelial ovarian cancer[J]. Transl Oncol, 2017, 10(3): 346-356. |
24 | ZHANG S P, CUI B, LAI H, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy[J]. Proc Natl Acad Sci USA, 2014, 111(48): 17266-17271. |
25 | FANG X, CHEN C Q, XIA F Z, et al. CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/cyclin D2 signaling[J]. J Hematol Oncol, 2016, 9(1): 124. |
26 | ASEM M, YOUNG A M, OYAMA C, et al. Host Wnt5a potentiates microenvironmental regulation of ovarian cancer metastasis[J]. Cancer Res, 2020, 80(5): 1156-1170. |
27 | LUO M, ZHOU L, ZHAN S J, et al. ALPL regulates the aggressive potential of high grade serous ovarian cancer cells via a non-canonical Wnt pathway[J]. Biochem Biophys Res Commun, 2019, 513(2): 528-533. |
28 | QI H, SUN B C, ZHAO X L, et al. Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Cα in epithelial ovarian cancer[J]. Oncol Rep, 2014, 32(2): 771-779. |
29 | AL-ALEM L F, MCCORD L A, SOUTHARD R C, et al. Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10[J]. Biol Reprod, 2013, 89(3): 73. |
30 | TANG Y Y, HE Y, ZHANG P, et al. LncRNAs regulate the cytoskeleton and related Rho/ROCK signaling in cancer metastasis[J]. Mol Cancer, 2018, 17(1): 77. |
31 | WANG S Z, WEI H, ZHANG S L. Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion[J]. BMC Cancer, 2017, 17(1): 455. |
32 | DEHGHANI-GHOBADI Z, SHEIKH HASANI S, AREFIAN E, et al. Wnt5a and TGFβ1 converges through YAP1 activity and integrin alpha v up-regulation promoting epithelial to mesenchymal transition in ovarian cancer cells and mesothelial cell activation[J]. Cells, 2022, 11(2): 237. |
33 | PARK H W, KIM Y C, YU B, et al. Alternative Wnt signaling activates YAP/TAZ[J]. Cell, 2015, 162(4): 780-794. |
34 | VESKIMÄE K, SCARAVILLI M, NIININEN W, et al. Expression analysis of platinum sensitive and resistant epithelial ovarian cancer patient samples reveals new candidates for targeted therapies[J]. Transl Oncol, 2018, 11(5): 1160-1170. |
35 | HUNG T H, HSU S C, CHENG C Y, et al. Wnt5a regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway[J]. Oncotarget, 2014, 5(23): 12273-12290. |
36 | ZHANG K, SONG H X, YANG P, et al. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling[J]. Cell Prolif, 2015, 48(2): 249-258. |
37 | HUANG L, JIN Y, FENG S J, et al. Role of Wnt/β-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca2+ pathways in cisplatin-induced chemoresistance in ovarian cancer[J]. Exp Ther Med, 2016, 12(6): 3851-3858. |
38 | HUANG W, YANG S, CHENG Y S, et al. Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKⅡ/CREB1 mediated ABCB1 expression[J]. Front Oncol, 2022, 12: 1068443. |
39 | WANG Y L, XU C L, WANG Y, et al. MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a[J]. Am J Cancer Res, 2017, 7(5): 1096-1106. |
40 | JENEI V, SHERWOOD V, HOWLIN J, et al. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion[J]. Proc Natl Acad Sci USA, 2009, 106(46): 19473-19478. |
41 | MOORE K N, GUNDERSON C C, SABBATINI P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer[J]. Gynecol Oncol, 2019, 154(2): 294-301. |
42 | CHOI M Y, WIDHOPF G F Ⅱ, WU C C, et al. Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1[J]. Clin Lymphoma Myeloma Leuk, 2015, 15: S167-S169. |
43 | CHOI M Y, WIDHOPF G F Ⅱ, GHIA E M, et al. Phase Ⅰ trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia[J]. Cell Stem Cell, 2018, 22(6): 951-959.e3. |
44 | GHIA E M, RASSENTI L Z, CHOI M Y, et al. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia[J]. Leukemia, 2022, 36(6): 1609-1618. |
45 | ZHANG S P, ZHANG H, GHIA E M, et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody[J]. Proc Natl Acad Sci USA, 2019, 116(4): 1370-1377. |
46 | LIU D L, KAUFMANN G F, BREITMEYER J B, et al. The anti-ROR1 monoclonal antibody zilovertamab inhibits the proliferation of ovarian and endometrial cancer cells[J]. Pharmaceutics, 2022, 14(4): 837. |
47 | WU D, YU X Y, WANG J, et al. Ovarian cancer stem cells with high ROR1 expression serve as a new prophylactic vaccine for ovarian cancer[J]. J Immunol Res, 2019, 2019: 9394615. |
48 | OSORIO-RODRÍGUEZ D A, CAMACHO B A, RAMÍREZ-SEGURA C. Anti-ROR1 CAR-T cells: architecture and performance[J]. Front Med (Lausanne), 2023, 10: 1121020. |
49 | LEE B K, WAN Y H, CHIN Z L, et al. Developing ROR1 targeting CAR-T cells against solid tumors in preclinical studies[J]. Cancers, 2022, 14(15): 3618. |
50 | SRIVASTAVA S, FURLAN S N, JAEGER-RUCKSTUHL C A, et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade[J]. Cancer Cell, 2021, 39(2): 193-208.e10. |
51 | JOSHI N, LIU D L, DICKSON K A, et al. An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles[J]. J Mater Chem B, 2021, 9(44): 9123-9135. |
52 | CHEN X Y, CHEN Y M, LIN X Y, et al. The drug combination of SB202190 and SP600125 significantly inhibit the growth and metastasis of olaparib-resistant ovarian cancer cell[J]. Curr Pharm Biotechnol, 2018, 19(6): 506-513. |
53 | OHTA T, TAKAHASHI T, SHIBUYA T, et al. Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells[J]. Cancer Biol Ther, 2012, 13(1): 25-33. |
[1] | MEI Yanqing, HAN Yujie, WENG Wenyun, ZHANG Lei, TANG Yujie. In vitro therapeutic effects and molecular mechanisms of targeted inhibition of CDK12/13 in high-grade gliomas [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 545-559. |
[2] | XU Yinglian, TIAN Jing, ZHANG Xiang, ZHAO Shunying. Research progress in the roles of airway epithelial cells in the pathogenesis of asthma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 619-623. |
[3] | WEI Lanyi, XUE Xiaochuan, CHEN Junjun, YANG Quanjun, WANG Mengyue, HAN Yonglong. Research progress of tumor-associated macrophages in immune microenvironment and targeted therapy of osteosarcoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 624-630. |
[4] | LIU Tiexin, LIN Junqing, ZHENG Xianyou. Research progress of subcellular structure-targeted therapy in spinal cord injury [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 230-236. |
[5] | HAN Yongqi, HAN Da, XIA Qian, JI Dingkun, TAN Weihong. Aptamer-drug conjugates (ApDCs): new trend for cancer precision therapy [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1176-1181. |
[6] | LI Ruonan, CHEN Xiaoke, XU Yuanyuan, TAN Qiang. Advances in postoperative adjuvant targeted therapy for patients with stage ⅠB-ⅢA non-small cell lung cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1612-1619. |
[7] | Jia-ling ZHANG, Feng-chun ZHANG, Ying-chun XU. Research progress in the systemic treatment for breast cancer with brain metastasis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 671-677. |
[8] | Yuan-xin HUANG, Dong-mei LAI. Application of proteomics to the study of gynecological diseases [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 233-240. |
[9] | LI Chao, MI Jian-qing, WANG Jin. Advances in Philadelphia chromosome-like acute lymphoblastic leukemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1294-1301. |
[10] | GAO Jing-ze, WU Xia. CXCL9 mRNA in ovarian tumor tissue and its relations with prognosis and characteristics of immune microenvironment [J]. , 2020, 40(4): 457-. |
[11] | QIU Xing-di, WU An-yue, LI Dong, HONG Zu-bei, GU li-ying, QIU Li-hua. Mechanism of TWEAK promoting macrophage-derived exosomal miR-7 to epithelial ovarian cancer cell through regulating Dicer [J]. , 2018, 38(7): 740-. |
[12] | XU Hua-li, LIU Wen-xue, SHEN Fang-qian, XI Xiao-wei. Effects of UBE3C on proliferation and invasion in ovarian cancer SKOV3 cells [J]. , 2018, 38(6): 610-. |
[13] | CAI Liu-yun, LUO Xiao-dong, LIANG Hao, HU Jian-guo. Inhibition of C2CD3 regulates the proliferation, invasion and migration of epithelial ovarian cancer through inhibiting Hedgehog pathway [J]. , 2018, 38(12): 1414-. |
[14] | TANG Zhong-yuan1, 2, ZHANG Ning2, 3, DI Wen2, 3, LI Wei-ping2, 3. Effect of 3-methyladenine on autophagy, migration and invasion in epithelial ovarian cancer cells under hypoxia [J]. , 2018, 38(10): 1152-. |
[15] | LI Dong, HU Yuan, WU An-yue, QIU Xing-di, QIU Li-hua . Exosomal miRNA-7 from TWEAK-stimulated macrophages inhibiting the invasion and migration of ovarian cancer cells [J]. , 2017, 37(6): 726-. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||